Evaluation of lipid parameters and correlations in patients with clinical atherosclerosis

Year 2025, Volume: 39 Issue: 4, 279 - 292, 30.10.2025

Sibel Kuraş

https://doi.org/10.18614/dehm.1813843

Abstract

BACKGROUND
We aimed to evaluate lipid profiles, atherosclerotic index ratios, and correlations as early diagnostic biomarkers for cardiovascular atherosclerotic diseases.
METHODS
The study included 30 individuals with clinical atherosclerosis who underwent coronary artery bypass grafting (CABG) and 30 healthy individuals without a history of cardiovascular disease. Routine lipid profile values of the individuals included in the study were obtained from the hospital database, and non- high-density lipoprotein (HDL) cholesterol, non-HDL/HDL, triglyceride (TG)/glucose, and TG/HDL ratios were calculated from these values. The accepted level of statistical significance was p<0.05. Comparisons between groups were conducted using the Mann-Whitney U test.
RESULTS
Clinical atherosclerosis patients demonstrated statistically higher levels of TG, non-HDL cholesterol, and very low-density lipoprotein (VLDL) cholesterol, whereas HDL cholesterol was statistically lower in comparison to the healthy individuals. Furthermore, the patient group demonstrated elevated TG/HDL, TG/glucose, and non-HDL/HDL ratios, while total cholesterol and low-density lipoprotein (LDL) cholesterol levels remained statistically insignificant.
CONCLUSION
It is important for a biomarker or method to be noninvasive rather than invasive. We suggest that atherosclerotic index rates, in addition to routine lipid parameters, have the potential to predict asymptomatic individuals or the severity of atherosclerosis. However, it is necessary to conduct studies with larger samples.

Keywords

Atherosclerosis , diagnostic biomarker , lipid parameters.

References

• 1. Cao M, Luo H, Li D, Wang S, Xuan L, Sun L. Research advances on circulating long noncoding RNAs as biomarkers of cardiovascular diseases. Int J Cardiol [Internet]. 2022 Apr 15 [cited 2023 Jun 19];353:109–17. Available from: https://pubmed.ncbi.nlm.nih.gov/35143876/
• 2. World Health Organisation. Cardiovascular diseases.
• 3. Sun X, Deng K, Zang Y, Zhang Z, Zhao B, Fan J, et al. Exploring the regulatory roles of circular RNAs in the pathogenesis of atherosclerosis. Vascul Pharmacol. 2021 Dec;141:106898.
• 4. Wang M, Cheng L, Xiang Q, Gao Z, Ding Y, Xie H, et al. Evaluation the role of cuproptosis-related genes in the pathogenesis, diagnosis and molecular subtypes identification of atherosclerosis. Heliyon. 2023 Oct;9(10):e21158.
• 5. Jebari-Benslaiman S, Galicia-García U, Larrea-Sebal A, Olaetxea JR, Alloza I, Vandenbroeck K, et al.Pathophysiology of Atherosclerosis. Int J Mol Sci. 2022 Mar 20;23(6):3346.
• 6. Kumar V, Abbas AK, Aster JC. Kan Damarları. In: Tuzlalı S, Güllüoğlu M, Çevikbaş U, editors. Robbins Temel Patoloji. İstanbul: Nobel Tıp Kitabevleri; 2014. p. 327–63.
• 7. Shi X, Wei YT, Li H, Jiang T, Zheng XL, Yin K, et al. Long non-coding RNA H19 in atherosclerosis: what role? Molecular Medicine. 2020 Dec 22;26(1):72.
• 8. Ren K, Xu XD, Yu XH, Li MQ, Shi MW, Liu QX, et al. LncRNA-modulated autophagy in plaque cells: a new paradigm of gene regulation in atherosclerosis? Aging. 2020 Nov 4;12(21):22335–49.
• 9. Libby P, Buring JE, Badimon L, Hansson GK, Deanfield J, Bittencourt MS, et al. Atherosclerosis. Nat Rev Dis Primers. 2019 Aug 16;5(1):56.
• 10. Xiang Q, Tian F, Xu J, Du X, Zhang S, Liu L. New insight into dyslipidemia‐induced cellular senescence in atherosclerosis. Biological Reviews. 2022 Oct 15;97(5):1844–67.
• 11. Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019 Jun 18;139(25).
• 12. Gupta KK, Ali S, Sanghera RS. Pharmacological Options in Atherosclerosis: A Review of the Existing Evidence. Cardiol Ther. 2019 Jun 12;8(1):5–20.
• 13. Kumric M, Urlic H, Bozic J, Vilovic M, Ticinovic Kurir T, Glavas D, et al. Emerging Therapies for the Treatment of Atherosclerotic Cardiovascular Disease: From Bench to Bedside. Int J Mol Sci. 2023 Apr 29;24(9):8062.
• 14. Hurtubise J, McLellan K, Durr K, Onasanya O, Nwabuko D, Ndisang JF. The Different Facets of Dyslipidemia and Hypertension in Atherosclerosis. Curr Atheroscler Rep. 2016 Dec 7;18(12):82.
• 15. Imtiaz C, Farooqi MA, Bhatti T, Lee J, Moin R, Kang CU, et al. Focused Ultrasound, an Emerging Tool for Atherosclerosis Treatment: A Comprehensive Review. Life. 2023 Aug 21;13(8):1783.
• 16. Wang JK, Li Y, Zhao XL, Liu YB, Tan J, Xing YY, et al. Ablation of P lasma Prekallikrein Decreases Low-Density Lipoprotein Cholesterol by Stabilizing Low-Density Lipoprotein Receptor and Protects Against Atherosclerosis. Circulation. 2022 Mar;145(9):675–87.
• 17. Meng F, Yan J, Ma Q, Jiao Y, Han L, Xu J, et al. Expression status and clinical significance of lncRNA APPAT in the progression of atherosclerosis. PeerJ. 2018 Jan 17;6:e4246.
• 18. Gimbrone MA, García-Cardeña G. Endothelial Cell Dysfunction and the Pathobiology of Atherosclerosis. Circ Res. 2016 Feb 19;118(4):620–36.
• 19. Aryal B, Suárez Y. Non-coding RNA regulation of endothelial and macrophage functions during atherosclerosis. Vascul Pharmacol. 2019 Mar;114:64–75.
• 20. Hanson M. Endothelial dysfunction and cardiovascular disease: the role of predictive adaptive responses. Heart. 2005 Jul 1;91(7):864–6.
• 21. Pober JS, Sessa WC. Evolving functions of endothelial cells in inflammation. Nat Rev Immunol. 2007 Oct;7(10):803–15.
• 22. Bordeianu G, Mitu I, Stanescu RS, Ciobanu CP, Petrescu-Danila E, Marculescu AD, et al. Circulating Biomarkers for Laboratory Diagnostics of Atherosclerosis—Literature Review. Diagnostics. 2022 Dec 13;12(12):3141.
• 23. Yusuf S, Hawken S, Ôunpuu S, Dans T, Avezum A, Lanas F, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. The Lancet. 2004 Sep;364(9438):937–52.
• 24. Nordestgaard BG. Triglyceride-Rich Lipoproteins and Atherosclerotic Cardiovascular Disease. Circ Res. 2016 Feb 19;118(4):547–63.
• 25. Borén J, Taskinen MR, Björnson E, Packard CJ. Metabolism of triglyceride-rich lipoproteins in health and dyslipidaemia. Nat Rev Cardiol. 2022 Sep 22;19(9):577–92.
• 26. Wu F, Juonala M, Jacobs DR, Daniels SR, Kähönen M, Woo JG, et al. Childhood Non-HDL Cholesterol and LDL Cholesterol and Adult Atherosclerotic Cardiovascular Events. Circulation. 2024 Jan 16;149(3):217–26.
• 27. Kosmas CE, Rodriguez Polanco S, Bousvarou MD, Papakonstantinou EJ, Peña Genao E, Guzman E, et al. The Triglyceride/High-Density Lipoprotein Cholesterol (TG/HDL-C) Ratio as a Risk Marker for Metabolic Syndrome and Cardiovascular Disease. Diagnostics. 2023 Mar 1;13(5):929.
• 28. Wang B, Hua J, Ma L. Triglyceride to High-Density Lipoprotein Ratio can predict coronary artery calcification. Pak J Med Sci. 2022 Jan 14;38(3).
• 29. Chauhan A, Singhal A, Goyal P. TG/HDL Ratio: A marker for insulin resistance and atherosclerosis in prediabetics or not? J Family Med Prim Care. 2021;10(10):3700.
• 30. Pahwa R, Jialal I. Atherosclerosis. 2024.
• 31. Schoch L, Alcover S, Padró T, Ben-Aicha S, Mendieta G, Badimon L, et al. Update of HDL in atherosclerotic cardiovascular disease. Clínica e Investigación en Arteriosclerosis. 2023 Nov;35(6):297–314.
• 32. Rosenson RS, Brewer HB, Ansell BJ, Barter P, Chapman MJ, Heinecke JW, et al. Dysfunctional HDL and atherosclerotic cardiovascular disease. Nat Rev Cardiol. 2016 Jan 1;13(1):48–60.
• 33. Casula M, Colpani O, Xie S, Catapano AL, Baragetti A. HDL in Atherosclerotic Cardiovascular Disease: In Search of a Role. Cells. 2021 Jul 23;10(8):1869.
• 34. Kjeldsen EW, Thomassen JQ, Frikke-Schmidt R. HDL cholesterol concentrations and risk of atherosclerotic cardiovascular disease – Insights from randomized clinical trials and human genetics. Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids. 2022 Jan;1867(1):159063.
• 35. Guijarro C, Cosín-Sales J. Colesterol LDL y aterosclerosis: evidencias. Clínica e Investigación en Arteriosclerosis. 2021 May;33:25–32.
• 36. Fernández-Friera L, Fuster V, López-Melgar B, Oliva B, García-Ruiz JM, Mendiguren J, et al. Normal LDL-Cholesterol Levels Are Associated With Subclinical Atherosclerosis in the Absence of Risk Factors. J Am Coll Cardiol. 2017 Dec;70(24):2979–91.
• 37. Wang HH, Garruti G, Liu M, Portincasa P, Wang DQH. Cholesterol and Lipoprotein Metabolism and Atherosclerosis: Recent Advances in Reverse Cholesterol Transport. Ann Hepatol. 2017 Nov;16:S27–42.
• 38. Ravnskov U, de Lorgeril M, Diamond DM, Hama R, Hamazaki T, Hammarskjöld B, et al. LDL-C does not cause cardiovascular disease: a comprehensive review of the current literature. Expert Rev Clin Pharmacol. 2018 Oct 3;11(10):959–70.
• 39. Raja V, Aguiar C, Alsayed N, Chibber YS, ElBadawi H, Ezhov M, et al. Non-HDL-cholesterol in dyslipidemia: Review of the state-of-the-art literature and outlook. Atherosclerosis. 2023 Oct;383:117312.
• 40. Castillo-Núñez Y, Morales-Villegas E, Aguilar-Salinas CA. Triglyceride-Rich Lipoproteins: Their Role in Atherosclerosis. Revista de investigacion Clinica. 2022 Mar 30;74(2).
• 41. Takahashi S. Role of VLDL receptor in atherogenesis. Curr Opin Lipidol. 2021 Aug;32(4):219–25.
• 42. Masson W, Epstein T, Huerín M, Lobo M, Molinero G, Siniawski D. Association between non-HDL-C/HDL-C ratio and carotid atherosclerosis in postmenopausal middle-aged women. Climacteric. 2019 Sep 3;22(5):518–22.
• 43. Wang K, Shan S, Zheng H, Zhao X, Chen C, Liu C. Non-HDL-cholesterol to HDL-cholesterol ratio is a better predictor of new-onset non-alcoholic fatty liver disease than non-HDL-cholesterol: a cohort study. Lipids Health Dis. 2018 Dec 21;17(1):196.
• 44. Wang A, Li Y, Zhou L, Liu K, Li S, Zong C, et al. Non-HDL-C/HDL-C ratio is associated with carotid plaque stability in general population: A cross-sectional study. Front Neurol. 2022 Sep 15;13.
• 45. Tao LC, Xu J ni, Wang T ting, Hua F, Li JJ. Triglyceride-glucose index as a marker in cardiovascular diseases: landscape and limitations. Cardiovasc Diabetol. 2022 Dec 6;21(1):68.
• 46. Lopez-Jaramillo P, Gomez-Arbelaez D, Martinez-Bello D, Abat MEM, Alhabib KF, Avezum Á, et al. Association of the triglyceride glucose index as a measure of insulin resistance with mortality and cardiovascular disease in populations from five continents (PURE study): a prospective cohort study. Lancet Healthy Longev. 2023 Jan;4(1):e23–33.